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Abstract
This perspective from a Regenerative Medicine Manufacturing Society working
group highlights regenerative medicine therapeutic opportunities for fighting
COVID-19. This article addresses why SARS-CoV-2 is so different from other viruses
and how regenerative medicine is poised to deliver new therapeutic opportunities to
battle COVID-19. We describe animal models that depict the mechanism of action
for COVID-19 and that may help identify new treatments. Additionally, organoid
platforms that can recapitulate some of the physiological properties of human organ
systems, such as the lungs and the heart, are discussed as potential platforms that
may prove useful in rapidly screening new drugs and identifying at-risk patients. This
article critically evaluates some of the promising regenerative medicine-based thera-
pies for treating COVID-19 and presents some of the collective technologies and
resources that the scientific community currently has available to confront this
pandemic.
K E YWORD S
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1 | INTRODUCTION
Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, led to
the spread of Coronavirus Disease 2019 (COVID-19) in December
2019 from Wuhan, China, to most of the world. COVID-19 is a respi-
ratory disease with wide spectrum of symptoms ranging from mild to
severe and involving many different organ systems. The list of
symptoms from the Centers for Disease Control and Prevention
(CDC) and the World Health Organization (WHO) continues to
change. As COVID-19 is a rapidly evolving disease, clinical experience
so far concludes that people aged >65 years are at a higher risk of
severe illness. Underlying medical conditions, such as lung and heart
diseases, immunodeficiency, obesity, diabetes, and kidney and liver
diseases, increase mortality risks.1 Among 4103 patients in New York
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City between 1 March, and 2 April, 2020, hospitalization risks were
greatest for those aged ≥75 years, with body mass index >40, and
with heart failure.2 New syndromes are still being described, including
skin symptoms and systemic inflammatory syndromes, such as sepsis
in adults and a Kawasaki-like syndrome in children.3-5
While the SARS-CoV-2 genome is 96% identical to bat coronavi-
rus and shares 79.6% sequence identity to SARS-CoV,6 the
COVID-19 mutant virus is believed to have a different diagnosis and
prognosis from the precedent forms. SARS-CoV-2 has a four-phase
infection paradigm. Phase 1 includes cell invasion and viral replication
through binding of the viral spike protein to a cell surface receptor
called ACE2.7 Phase 2 includes replication of SARS-CoV-2 in the lung
and immune system activation. In more severe cases, phase 3 includes
pneumonia, and in the most severe cases, phase 4 includes acute
respiratory distress syndrome, a cytokine storm, sepsis, and multiple
organ failure. A cytokine storm is characterized by cascades of inflam-
matory cytokines being released systemiclly, including IL-6, which has
been tied to increased damage in the lungs and other organs.8,9 Cur-
rent standard of care treatment for COVID-19 patients across these
phases can be found on the CDC website, where guidelines are pro-
vided for the medical management of COVID-19 and have been publi-
shed by the National Institutes of Health (NIH).10
Regenerative medicine is uniquely poised not only to provide
solid understanding of the infection mechanism and ways to prevent
it, but also to introduce innovative treatments other than drugs.
Figure 1 captures the phases and clinical symptoms of COVID-19, as
well as innovative ways to model and treat the disease, including
organoids, immunomodulatory effects, and regenerative effects.
Organoids are self-organizing cellular three-dimensional (3D) struc-
tures in an extracellular matrix (ECM). Organoid technology is a pow-
erful tool for disease modeling in vitro, as they can replicate essential
structural and functional aspects of organs in a dish. Alveolar
organoids could improve our understanding of the antiviral inflamma-
tory response and expedite the development of therapies.11 Lung
organoids also offer a way to study differences in how the virus
infects the lung cells of different patients and how patients might
F IGURE 1 Different approaches for fighting COVID-19. Illustrated in this graphic figure are (a) phases and clinical symptoms of COVID-19,
(b) models for COVID-19, (c) advanced organoid systems for drug screening and personalized medicine, and (d) regenerative medicine approaches
for treating COVID-19
Significance statement
Regenerative medicine is uniquely positioned to provide
advanced organoid models to understand the infection
mechanism of, identify patients at risk for, and develop ways
to prevent COVID-19, as well as to introduce innovative
treatments that have immunomodulatory and regenerative
properties. The Regenerative Medicine Manufacturing Soci-
ety (RMMS) and STEM CELLS Translational Medicine (SCTM)
collaborated to create a platform on the STEM CELLS Portal
(https://stemcellsportal.com/regenerative-medicine-covid-
19-resources) for sharing regenerative medicine resources
to address the COVID-19 pandemic in three areas: models,
cell therapies, and technologies. This information will be
made publicly available and developed further by RMMS in
future webinars and perspective articles.
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respond to tailored treatments. Other organ-specific organoids, such
as the kidney or liver, can be applied to developing therapies to pre-
vent COVID-19-related organ failure.
The immunomodulatory effect of stem cell therapies has gained a
rapidly growing interest during the COVID-19 pandemic. At this writ-
ing, there are 94 clinical trials listed on ClinicalTrials.gov that are
related to stem cells used for COVID-19 therapy. Mesenchymal stro-
mal/stem cells (MSC) have the ability to secrete a variety of endo-
somes and factors that reduce damaging inflammation, and several
clinical trials involve administration of MSCs to COVID-19 patients.12
Intravenous MSC infusion showed a reduction in inflammatory cell
types and cytokines, such as tumor necrosis factor, and an increase in
anti-inflammatory cytokines, such as interleukin 10 (IL-10). Gene
expression profiles showed that MSCs were angiotensin-converting
enzyme 2-negative (ACE2-) and transmembrane serine protease
2-negative (TMPRSS2-), which indicated MSCs were resistant to
COVID-19 infection.13 MSCs have also been shown to assist with
sepsis14,15 and reduce inflammation.16
The goals of regenerative medicine—to repair, regenerate, and
restore missing function or tissue—might drive the investigation of
several regenerative therapies for COVID-19-recovered patients. In a
retrospective, observational study on critically ill patients with SARS-
CoV-2 pneumonia,17 the authors reported that most patients had
organ function damage, including 67% with acute respiratory distress
syndrome (ARDS), 29% with acute kidney injury, 29% with cardiac
injury, and 29% with liver dysfunction. Moreover, type II pneumocytes
in the lung are a major target of SARS-CoV, propagating new virus
and suffering widespread damage. Type II pneumocytes express ACE2
and associated enzymes transmembrane protease serine 2 (TMPRSS2)
and Cathepsin L (CTSL).18 Lung progenitor cells (CD34 + Oct4+) can
be preferentially infected by SARS-CoV (2003 version) compared with
more mature pneumocytes.19 Taken together, these findings mean
that as COVID-19-infected lungs try to replace damaged and dead
lung cells, the replacement stem and progenitor cells may also be
targeted by the virus in a one-two punch. This may be behind the long
periods of time it takes for patients to recover, as well as the lung
scarring that may reduce lung capacity, perhaps permanently for some
patients. After the pandemic is past, there will be a lasting population
of patients who need long-term therapy to regain lost lung function.
Any treatment that can boost the regenerative power of lung tissues
by replacing these critical stem cells will help a large new patient
population.
2 | SMALL ANIMAL MODELS FOR
COVID-19
The use of the standard laboratory mouse has been limited because
of the mismatch in the ACE2 receptor sequence between mouse and
humans. Mice genetically engineered to carry the human ACE2 gene
for research on SARS-CoV are rapidly being assessed for their use in
the study of COVID-19. Two models, the B6.Cg-Tg(K18-ACE2)
2Prlmn/J mice and the Tg(FOXJ1-ACE2)1Rba mice, have been made
available to researchers by public repositories. The Tg(FOXJ1-ACE2)
1Rba is from the Mouse Mutant Research and Resource, stock
MMRRC:066719, and the B6.Cg-Tg(K18-ACE2)2Prlmn/J mouse is
available from The Jackson Laboratory, JAX:034860. Their response
to SARS-CoV2 is not clear at this time.
Compared with mouse models, Syrian hamsters present more
human-like disease symptoms and pathogenesis with viruses like
Ebola,20 and their immune responses are more similar to humans.21
Studies of SARS-CoV in Syrian hamsters noted viral replication in the
lungs with clearance in 7 days; however, the hamsters did not pro-
gress to ARDS.22 While Syrian hamsters clearly have their niche in
infectious diseases, there are also limitations to their use. Species-
specific reagents such as antibodies are scarce. Still, while the Syrian
hamster is a promising model for the study of COVID-19, their limited
commercial availability and widespread use present practical limita-
tions in their high throughput use.
Ferrets are good models for respiratory diseases, as their lung and
airway physiology are close to humans. Unlike rodents, ferrets cough
and sneeze, making them a useful model of disease transmission.
When infected with SARS-CoV-2, ferrets have elevated temperatures,
lethargy, and appetite loss but do not progress to ARDS. There are
also few research facilities capable of working with ferrets, which
have complicated animal husbandry requirements and a limited com-
mercial supply.23
Each animal model offers advantages that will be useful, not only
for the testing of therapies, but also for understanding related co-mor-
bidities. Interested readers are referred to this excellent reference,
which compares 10 different animal models in the search for the best
model to study COVID-19.24
3 | ADVANCED ORGANOID SYSTEMS FOR
MODELING COVID-19
Organoids can model organ function in-vitro, providing a more acces-
sible, faster, and higher throughput screening tool than in vivo models.
There are a few methods to engineer organoids, including manual 3D
culture, liquid handling, or 3D bioprinting. All of these methods can
use ECM in the process, which results in cell assembly that recapitu-
lates organ function on a small scale and can help model different clin-
ical features of COVID-19.25 Using organoids to model organ function
and infection by the SARS-CoV-2 virus can be a valuable tool to
gather more insights on its viral tropism and pathogenesis, as well as
serve as a platform to find potential treatment strategies for COVID-
19. While initial studies with SARS-CoV-2 have used Vero E6 cells,
using models of the lung, heart, kidney, and intestine can be crucial to
new therapies.
Lung organoids have previously been used to model infections by
different pathogens. Hui et al. developed human lung organoids that
recapitulate the bronchial airway, including cilia, goblet cells, club cells,
and basal cells.26 They then successfully infected these organoids with
the influenza virus, analyzing replication competence, tissue tropism,
and host responses. Their results were comparable to those observed
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in human ex vivo bronchus cultures, offering a viable alternative for
modeling viral infections in the lung.
Similarly, Monteil et al used SARS-CoV-2-infected human kidney
organoids to investigate the effectiveness of human recombinant sol-
uble ACE2 (hrsACE2) in inhibiting viral growth.27 Liver organoids were
also utilized to investigate how this tissue is infected and damaged by
SARS-CoV-2. Zhao et al found evidence to support the hypothesis
that COVID-19 patient liver damage might be resultant from cho-
langiocyte injury and consequent bile acid accumulation caused by
the viral infection.28 These results indicate that organoids are a pow-
erful tool in understanding mechanisms through which SARS-CoV-2
affects liver tissue.
Although cardiac organoid infection by the SARS-CoV-2 virus has
not been characterized, cardiac organoids could be a feasible platform
for use in COVID-19 drug screening. Mills et al, for example, devel-
oped a high-throughput bioengineered human cardiac organoid plat-
form, using it to screen 105 small molecules with regenerative
potential.29 These organoids could also be used to study how the
heart is affected by COVID-19.
The intestine is another target organ for the SARS-CoV-2 virus,
with a high expression of ACE2 in intestinal enterocytes. Lamers et al.
developed human small intestinal organoids (hSIOs) that were readily
infected by SARS-CoV and SARS-CoV-2 viruses.30 Their study indi-
cated enterocytes as the target cell for infection in the intestine, dem-
onstrating that intestinal organoid cultures can be a key method for
better understanding viral biology.
Immune organoid culture can also contribute to understanding
COVID-19 immune responses.31 Organoids are a useful tool to inves-
tigate and characterize organ function and disease progression, and
they should be further explored as a high-throughput, highly specific
platform for COVID-19 drug screening.
Human in vitro tissue-on-a-chip platforms enable the direct use
of human heart cells to evaluate potential effectiveness of existing or
new COVID-19 drugs (Figure 2). Additionally, using cells from a
diverse patient population, including both sexes, may help classify the
cardiovascular and pulmonary risk of COVID-19 drugs. Additionally,
there is need to screen repurposed drugs for COVID-19 for toxicity,
and an excellent review has evaluated current therapeutic drugs for
the treatment of COVID-19 patients.32
Tissue chips using lung airway epithelium that express high levels
of ACE2 and TMPRSS2 have been used to screen repurposed drug
candidates for inhibition of SARS-CoV-2 viral entry.27 When used to
assess seven clinically approved drugs (chloroquine, arbidol, tor-
emifene, clomiphene, amodiaquine, verapamil, and amiodarone), only
toremifene and amodiaquine were found to inhibit viral entry. These
results suggested that human tissue chip technology screening assays
could be used to study human disease pathogens and expedite drug
repurposing.33 Figure 2 highlights how organ toxicity of COVID-19
drugs could be evaluated using these organoid tissue chips, where
advances in connecting these organ chips to achieve multi-tissue
interactions will be important to detect unanticipated drug toxicity.34
Taken together, employing an advanced organoid tissue chip can
reduce the cost and time needed to develop new treatments, due to
the ability to test so many compounds across these different organ
systems, which could be created for thousands and thousands of
patients. This idea is in fact being taken to a new level by the NIH,
which has deployed funding opportunities for clinical trials on a chip.
The future will harness these tissue chips and use large data reposito-
ries to essentially perform clinical trials using patient-derived organoid
models.
4 | REGEN MED THERAPIES FOR
COVID-19
Patients suffering from severe COVID-19 have increased
proinflammatory cytokine levels, including increased IL-6 levels that
can be part of the cytokine storm or cytokine release syndrome
(CRS).35 CRS is not new to the regenerative medicine industry. Chime-
ric antigen receptor T-cell therapy (CAR-T), the first FDA-approved cell
therapy, can elicit CRS. Since the beginning of the current pandemic,
the regenerative medicine industry has rapidly pivoted to translate the
lessons learned from mitigating CRS in CAR-T therapy to COVID-19.36
Recent results from the Randomized Evaluation of COVID-19 Therapy
(RECOVERY) trial (ClinicalTrials.gov Identifier: NCT04381936) con-
firmed that patients hospitalized with COVID-19 receiving dexametha-
sone (a corticosteroid medication) resulted in lower 28-day mortality
among those receiving either mechanical ventilation or oxygen alone.37
This study supports the tremendous benefits of large randomized stud-
ies in evaluating interventions for COVID-19. Previous clinical data did
not support the use of corticosteroid treatment for COVID-19-related
lung injury.38 Therefore, there is an emergent need for more large ran-
domized trials, such as RECOVERY, to develop new treatments for
COVID-19-associated CRS and ARDS.
F IGURE 2 Advanced organoid tissue chips for evaluating organ
toxicity of COVID-19 drugs. This figure shows how testing could be
performed using organoid tissue chips to screen potential toxicity in
drug candidates
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MSCs are the leading potential allogeneic cellular therapy candi-
date for ARDS and CRS.39 Once at the site of infection, MSCs release
anti-inflammatory cytokines and act through cell-cell contact to help
regulate the local environment. Early studies in China have demon-
strated the efficacy of MSCs in COVID-19 patients and some have
already been published.13 Outside of China, promising results in small
cohorts have already shown some success and been announced.
Pluristem Therapeutics showed that infusion of placenta-derived
“mesenchymal-like cells” in COVID-19 patients with ARDS on
mechanical ventilation led to improvements in four of six patients.40
Under emergency use, RESTEM recently showed promising results
from infusion with experimental umbilical cord lining-derived stem
cells in three COVID-19 patients with ARDS. On the basis of these
results, the RESTEM has received FDA approval for a 60-patient
phase I/II clinical trial.41 The University of Miami Medical School also
has FDA approval to test cryopreserved allogenic umbilical cord stem
cells on 12 COVID-19 patients.42 In terms of the allogeneic approach
with bone-marrow derived MSCs, Remestemcel-L, developed by
Mesoblast, has an encouraging potential after 9 of 12 moderate to
severe COVID-19 patients successfully came off ventilators within
10 days of two infusions.43 Athersys also released positive 28-day
data with 1-year follow-up on an ARDS trial using MultiStem, which
showed improvement in survival and improvements in ventilator
dependency. As a result, the MultiStem has been given fast-track des-
ignation by the FDA, and MACOVIA, a pivotal phase II/III trial will
enroll ~400 COVID-19 patients. The FDA also recently approved a
phase II single-arm study for Hope Biosciences (Houston, TX) to enroll
75 high-risk participants using autologous, adipose-derived MSCs.44
In addition to these trials, more than 200 additional MSC-related clini-
cal trials for COVID-19 have been registered on ClinicalTrials.gov as
of August 10, 2020. This fairly extensive clinical effort to develop an
MSC therapy includes sources from umbilical cord, bone marrow, adi-
pose tissue, and dental pulp. Leveraging some early positive results,
more extensive well-designed clinical trials are ongoing, which will be
critical in establishing the effects of MSC treatments on COVID-19
patient survival and accelerated recovery.
Regulatory T cell (Treg) transfusion may also be efficacious
against COVID-19 associated CRS. Like MSCs, Tregs reduce immune
responses and play a role in the prevention of autoimmunity, allergy,
organ transplant rejection, and other inflammatory immune
responses.45 Allogeneic Treg therapy has been explored as a treat-
ment for amyotrophic lateral sclerosis. Recently, Cellenkos46 submit-
ted a clinical development proposal to the Biomedical Advanced
Research and Development Authority (BARDA) for phase I/II clinical
trials for COVID-19 using cord blood Tregs.
Capricor Therapeutics recently announced that treatment with
allogeneic cardiosphere-derived cells led to four of six COVID-19
patients being removed from mechanical ventilation within 1-4 days
post-transfusion. As a result of this success, the US FDA has approved
the company’s expanded access protocol allowing for treatment of
twenty additional COVID-19 patients.47 While early results are very
promising, these preliminary reports lack proper control arms and pla-
cebos, and further trials are necessary.
Rather than quashing immune responses, boosting immune
responses using natural killer (NK) cells also has been proposed as a
treatment for severe COVID-19. Celularity Inc. recently received FDA
approval to initiate a trial in 86 COVID-19 patients. Celularity’s pla-
cental stem cell-derived NK cells may be able to target and eliminate
virally infected cells; however, there are risks that NK cells may add to
COVID-related inflammation and that they might not be able to
detect which cells are infected.48
Overall, regenerative medicine offers tremendous hope for
treating COVID-19, and initial clinical trial results are promising. How-
ever, properly designed and conducted clinical trials, with appropriate
enrollment, controls, and evaluation, are still needed.
5 | TECHNOLOGIES AND RESOURCES TO
FIGHT COVID-19
With great challenges come great opportunities for the scientific com-
munity. Several resources have been made available to combat
COVID-19 over a short period of time since the deceleration of the
pandemic. In the future, we envision doing more with less, fully auto-
mating standardized workflows, using artificial intelligence (AI) to mine
data and develop learning and predictive algorithms and using modu-
lar GMP environments to optimize manufacturing processes.
Social distancing requirements will be imposed on laboratories in
response to the COVID-19 pandemic, so automation will improve the
standard workflow in the laboratory and minimize the use of people
and personal protective equipment. Recent publications discuss auto-
mation and standardization of processing for a potential miRNA
marker candidates.49,50 For instance, the Revos Tissue Processor
(Thermo-Fisher) and high resolution slide scanners, such as those from
3DHISTECH, reduce labor time and maintain efficiency during
reduced staff schedules. It will also be advantageous to pair these
technologies with archiving solutions like the ARCOS platform from
EPREDIA for efficient data storage and recovery and potentially to be
combined with machine learning and predictive algorithms. With
remote access to images, research can continue even during limited
access to a facility. Building upon this, the adoption of cloud-based AI
solutions further enables remote access to data. One such ecosystem,
a spin-off from Memorial Sloan Kettering Hospital, has assisted in
accelerating biomarker discovery by PAIGE.AI.51
Cell therapies production models are moving toward closed sys-
tems to reduce contamination risks. Closed bioreactors are gaining
traction for cell expansions steps. Closed, modular cGMP cell produc-
tion environments that can enclose all the cell production steps from
start to finish are available and will be implemented in a post-COVID-
19 world. These systems have flexibility to be configured in non-GMP
space and validated in weeks. The clonability of the system means
that once conditions are optimized for production of the most potent
cell product (O2, CO2, temperature, humidity), those same conditions
can be verifiably reproduced anywhere in the world. This adds scien-
tific reproducibility and reliability to distributed COVID-19 organoid
and cell therapy production models.
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A new potential resource is the use of commercially available
small satellites in low Earth orbit to be used as a microgravity research
platform, in conjunction with tissue chip/lab-on-a-chip technology
and/or microfluidic devices such as what the National Center for
Advancing Translational Science is working on in collaboration with
the Defense Advanced Research Projects Agency and the Food and
Drug Administration.52 Companies and research institutions are
finding considerable value in exploring the effects of the space envi-
ronment on human health, pharmaceuticals, biotechnology/bioengi-
neering, and advanced manufacturing. In fact, studies have shown
that microgravity can cause various pathogens to become more
virulent,53 which has a genetic component,54 and this could be used
to develop accelerated disease progression models in organoids
infected with the SARS-CoV-2 virus. The space environment has
properties not found in terrestrial environments, which includes
microgravity, hard vacuum, and space radiation. These properties have
surprising effects on cellular and molecular processes. Opportunities
exist for elucidating molecular mechanisms in microgravity, studying
complex fluid dynamics, testing materials, analyzing proteins and large
molecules, and advancing the science of nanofluidics and biotechnol-
ogy. For example, Orbital Transports, Inc., is developing solutions for
performing cellular and molecular research on small satellites by using
a suitably sized bioreactor, tissue chip/lab-on-a-chip technology,
and/or microfluidic devices. This will enable new opportunities for
space-based research that can be conducted without human interven-
tion, and thus, free the scientist from crew time and other limitations
inherent to the mission of the International Space Station.
The world’s leading journals are providing free access to COVID-
19-related papers and resources. The New England Journal of Medicine
has a COVID-19 landing page that compiles all of their COVID-19 con-
tent.55 The Lancet also has a resource center focused on COVID-19 and
provides free access.56 The journal Nature’s newsletter, Nature Briefing,
is a weekly gathering of the latest information.57 COVID-specific litera-
ture web search engines, such as COVID Scholar,58 have also appeared.
Utilizing these free reliable resources will give you the latest, substanti-
ated scientific developments under way to combat COVID-19.
The US FDA has done an outstanding job in response to COVID-
19. The FDA has fast-tracked potential treatments (~60 day review)
and has been very responsive in approving Emergency Use Authoriza-
tions. They also have a dedicated specific resources: Coronavirus Dis-
ease 2019 (COVID-19),59 Emergency Use Authorizations,60 and
Coronavirus Treatment Acceleration Program (CTAP).61 Additional
resources to get the complete picture of the developments taking place
are also available at the following organizations: World Health Organi-
zation (WHO),62 Centers for Disease Control and Prevention (CDC),63
John Hopkins,64 Chinese CDC,65 and Gates Notes.66 The Atlantic has
developed The COVID Tracking Project67 to focus on the incredibly
important topic of testing and compiles the most accurate data avail-
able. Eva Garland Consulting LLC has done a great job of compiling and
continuously updating the grants opportunities.68 CellTrials.org also
provides a free report on all registered COVID-19 trials.69
COVID-evidence70 is a non-profit initiative of the Department of
Clinical Research at University of Basel and the Meta-Research Innovation
Center at Stanford, with other international partners and collaborators,
which provides a continuously updated free database on interventions for
COVID-19. BioCentury has a COVID-19 Resource Center71 with an infor-
mation portal on COVID-19 therapies and vaccines (clinical and preclini-
cal), COVID-19 trial timeline, diagnostics, status of regulatory meetings,
resources for researchers, and a COVID-19 research gateway where com-
panies and researchers are provided an intake form to submit their latest
advances on compounds, diagnostics, preclinical assays, clinical trial
designs, protocols, sites, data or data-sharing resources, and inquiries
about COVID research and development.
The Regenerative Medicine Manufacturing Society (RMMS) and
STEM CELLS Translational Medicine (SCTM) have created a page on the
STEM CELLS Portal for regenerative medicine resources in the fight
against COVID-19. This page provides a COVID-19 Resource Submis-
sion Page72 for scientists (academic, industry, government, non-profits,
etc.) to highlight regenerative medicine resources directed against
COVID-19 in three areas: (a) models, (b) cell therapies, and
(c) technologies. These resources will be presented in a redacted format
(type of regenerative medicine resource / institution / resource descrip-
tion) on the Regenerative Medicine COVID-19 Resources Results
Page73 and shared with RMMS working group co-leads to continue
meaningful discussions within the working groups and also to plan
future webinars and perspective articles to disseminate these important
regenerative medicine resources to the entire scientific community.
Those wishing to become involved in RMMS working groups are
encouraged to visit our website (http://regenmedmanufacturing.org/
membership/) and sign up to be a member.
The scientific community continues to work diligently and coop-
eratively to combat COVID-19 and the coronavirus. Through collabo-
ration, reliance on real-world evidence, and a willingness to roll up our
sleeves and get to work, we will overcome this pandemic together.
6 | CONCLUSIONS AND FUTURE
DIRECTIONS
Regenerative medicine is poised to make a true difference in the fight
against COVID-19. We have reviewed some of the advances in
organoid systems to model COVID-19 symptoms that could be used
for developing new treatments or screening at-risk patients. We have
also covered some of the effects regenerative medicine-based thera-
pies may have on treating COVID-19-related symptoms, such as
immunomodulatory effects or even regenerative effects. We have dis-
cussed technologies and resources that are currently available to con-
front COVID-19. It is times like these when we must all come
together, share our talents and resources, and develop the best
methods, technologies, and capabilities to address global health
challenges.
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